Isotechnika Pharma Inc IPHAF

RE: variability in trial results

[labumba]

I totally agree with JJgoo1.

TeeVee, you are a moron....you are still spreading fear and throwing all kind of craps... what you are implying day in and day out that  this company is hopeless and going to bankcruptcy with a drug that won't make it to the market.......

 listen ..acute rejection has never been an issue with Cyclosporin ....the successful rate of  maintaining the graft survival is over 90%.....listen one more time, the Cyclosporin is as good as Profgrat in dealing with acute rejection....only the nephrotoxcity is an issue for Cyclosporin

Now, if you compare the mid dose of Voclosporin with Tac in GFR and Serum Creatinine level, the data are quite close like  Gfr 64 ml/min of  Voc vs Gfr 65 of Voc and Serum creatinine 123 mol/liter of Voc  vs 120 of Tac ( Tac arm also has a better baseline of Serum creatinine level to start with due to a higher % of kidneys from live doners ), furthermore, ....dosage can be pesonalized to a patient's need according to his/ her  the trough blood concentration and PK and PD. They can dial down from .8 mg/kg to .6 once the patient is stabilized after transplanted......

Historically,  Tac is better off than Cyclosporin in terms of nephrotoxcity .  the trial data  of Voclo shows a  far better safety profile in kidney function in comparing with the historical data of Cyclosporin . So is it Tac is far better off than Voclo in kidney function. Only the long term data can tell......by the way, check both the mechanism of action of Voclo and Cyclosporin